Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Oryzon Genomics's Iadademstat?
Iadademstat is a small molecule commercialized by Oryzon Genomics, with a leading Phase II program in Neuroendocrine Carcinoma. According to...
Data Insights
Iadademstat by Oryzon Genomics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Iadademstat is under clinical development by Oryzon Genomics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...